View Post This content is machine translated Tolerability Check On the downside: throat and liver In terms of tolerability, ozanimod compares favorably with other sphingosine-1-phosphate receptor modulators [1–3]*. In the pivotal studies, drop-out rates due to adverse events were approximately 3%, with comparable rates in each of the different treatment groups. The adverse drug reactions most commonly observed during ozanimod therapy were nasopharyngitis, upper respiratory tract infections, urinary tract infections, elevated alanine aminotransferase and γGT levels, hypertension, and headache…. This content can only be access by registered users. Log In Register View Post
View Post This content is machine translated Safety Check Selectivity as a distinguishing feature Like any form of intervention in the human immune system, therapy with Ozanimod carries certain risks. In particular, infections and adverse cardiac effects represent previously known side effects of treatment with S1P receptor modulators. However, the pivotal studies of ozanimod, as well as other data since their completion, suggest a comparatively favorable safety profile [1–3]…. This content can only be access by registered users. Log In Register View Post
View Post This content is machine translated Efficacy Check Multiple levels of effectiveness The two completed phase III studies SUNBEAM [1] and RADIANCE [2] were able to demonstrate the efficacy of the new active substance in the area of other – radiological and clinical – endpoints in addition to a reduction in relapse frequency through therapy with ozanimod. For the first time in MS research, a slowing of brain volume decline was observed in the cortical gray matter and thalamus…. This content can only be access by registered users. Log In Register View Post
View Post This content is machine translated Ozanimod A new player in MS therapy With the recently approved ozanimod, another potent compound for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator demonstrated good efficacy and a safety profile comparable to interferon β1a in two randomized multicenter phase 3 trials with a total of over 2600 participants [1,2]. A large follow-up study that included nearly 85% of patients continues to provide consistent results [3]…. This content can only be access by registered users. Log In Register View Post
View Post This content is machine translated MS therapy today A new player in MS therapy With the recently approved ozanimod, another highly potent agent for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator demonstrated high efficacy and a safety profile comparable to interferon β1a in two randomized multicenter phase 3 trials with a total of over 2600 participants. A large follow-up study, which included nearly 85% of patients, continues to yield promising results…. This content can only be access by registered users. Log In Register View Post
